drugset / Trial / NCT03327727
VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.
Timeline
- Start
- 2018-02-20
- Primary completion
- 2019-01-14
- Completion
- 2019-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B | Unknown | — | — |
| Subject | Isavuconazole | Small molecule | — | — |
| Subject | VL-2397 | Unknown | 600 mg | Intravenous |
| Subject | Voriconazole | Small molecule | — | — |